Sorry I find that hard to buy. If they sold the shares in the treasury it would bring in over $300million (at $1/share) Raising the A/S gives them the potential to raise slightly over $500 million.
But if $300 million isn't enough to launch the drug, they have a serious problem and the drug would have priced out the market to make-up the expense.